Ingevity (FRA:IGX) Cyclically Adjusted Revenue per Share: €30.82 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:IGX Ingevity Corp FRA:IGX
62 GF Score
Price €61.50
GF Value €36.78
! 6 Warning Signs
View Full Analysis

What is Ingevity Cyclically Adjusted Revenue per Share?

Ingevity FRA:IGX -3.15% 62 Cyclically Adjusted Revenue per Share is €30.82 as of Mar. 2026. GuruFocus rates FRA:IGX with a GF Score™ of 62/100 and a GF Value™ of €36.78. The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Ingevity's adjusted revenue per share for the three months ended in Mar. 2026 was €6.196. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €30.82 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Ingevity's average Cyclically Adjusted Revenue Growth Rate was 4.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-22), Ingevity's current stock price is €61.50. Ingevity's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €30.82. Ingevity's Cyclically Adjusted PS Ratio of today is 2.00.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Ingevity was 2.11. The lowest was 0.88. And the median was 1.34.


Ingevity  (FRA:IGX) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Ingevity's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=61.50/30.82
=2.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Ingevity was 2.11. The lowest was 0.88. And the median was 1.34.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Ingevity Cyclically Adjusted Revenue per Share Related Terms


Ingevity Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Ingevity's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ingevity Cyclically Adjusted Revenue per Share Chart

Ingevity Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 33.28 30.71

Ingevity Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.99 29.24 29.25 30.71 30.82

FRA:IGX vs KWR, MTX, ASH: Cyclically Adjusted Revenue per Share Comparison

For the Specialty Chemicals subindustry, Ingevity's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ingevity Cyclically Adjusted PS Ratio vs Chemicals Industry

For the Chemicals industry and Basic Materials sector, Ingevity's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Ingevity's Cyclically Adjusted PS Ratio falls into.


FRA:IGX
62GF Score
Ingevity Corp FRA:IGX
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ingevity Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ingevity's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=6.196/330.2130*330.2130
=6.196

Current CPI (Mar. 2026) = 330.2130.

Ingevity Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 5.185 241.018 7.104
201609 5.341 241.428 7.305
201612 4.702 241.432 6.431
201703 4.821 243.801 6.530
201706 5.460 244.955 7.360
201709 5.208 246.819 6.968
201712 4.557 246.524 6.104
201803 4.478 249.554 5.925
201806 6.199 251.989 8.123
201809 6.252 252.439 8.178
201812 5.758 251.233 7.568
201903 5.800 254.202 7.534
201906 7.398 256.143 9.537
201909 7.663 256.759 9.855
201912 6.471 256.974 8.315
202003 6.216 258.115 7.952
202006 5.808 257.797 7.439
202009 6.794 260.280 8.619
202012 6.457 260.474 8.186
202103 6.611 264.877 8.242
202106 7.378 271.696 8.967
202109 8.101 274.310 9.752
202112 7.524 278.802 8.911
202203 8.852 287.504 10.167
202206 10.251 296.311 11.424
202209 12.766 296.808 14.203
202212 9.599 296.797 10.680
202303 9.766 301.836 10.684
202306 12.151 305.109 13.151
202309 11.485 307.789 12.322
202312 -2.643 306.746 -2.845
202403 8.628 312.332 9.122
202406 9.987 314.175 10.497
202409 8.241 315.301 8.631
202412 6.918 315.605 7.238
202503 6.254 319.799 6.458
202506 8.682 322.561 8.888
202509 7.680 324.800 7.808
202512 6.096 324.054 6.212
202603 6.196 330.213 6.196

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €30.82 mean?
Ingevity (FRA:IGX) has a Cyclically Adjusted Revenue per Share of €30.82 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Ingevity and its competitors.
Is Ingevity's Cyclically Adjusted Revenue per Share too high?
Ingevity's current Cyclically Adjusted Revenue per Share is €30.82. Overall, Ingevity has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does Ingevity's Cyclically Adjusted Revenue per Share compare to KWR and MTX?
Ingevity's Cyclically Adjusted Revenue per Share of €30.82 can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Chemicals company?
A good Cyclically Adjusted Revenue per Share depends on the Chemicals industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Ingevity and its competitors. Ingevity's current Cyclically Adjusted Revenue per Share is €30.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ingevity stock overvalued right now?
Ingevity (FRA:IGX) has a current Cyclically Adjusted Revenue per Share of €30.82. The stock's GF Value™ is €36.78, compared to a current price of €61.50 — trading 67.2% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €30.82. Ingevity's overall GF Score™ is 62/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Ingevity (FRA:IGX), the current Cyclically Adjusted Revenue per Share is €30.82 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ingevity (FRA:IGX) Overvalued in 2026?

Based on GuruFocus' analysis, Ingevity stock appears to be overvalued. The current stock price of €61.50 is trading 67.2% above its estimated GF Value™ of €36.78.

Key valuation signals for FRA:IGX:

  • Cyclically Adjusted Revenue per Share: €30.82
  • GF Value™: €36.78 vs. price of €61.50 (67.2% above fair value)
  • GF Score™: 62/100 with 6 warning signs

No single metric tells the full story. See the FRA:IGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ingevity Business Description

Other Exchanges NGVT:USAIGX:Germany
Address 4920 O\'Hear Avenue, Suite 400, North Charleston, SC, USA, 29405
Ingevity Corp is a chemical manufacturer based in the United States. It conducts its operations through three segments, namely Performance Chemicals, Advanced Polymer Technologies, and Performance Materials. The bulk of its revenue is generated by the Performance Chemicals segment which deals with the manufacture and sale of specialty chemicals that find their use in a range of processes such as asphalt paving, oil exploration and production, agrochemicals, adhesives, lubricants, and publication inks. The Performance Materials segment, on the other hand, focuses on automotive carbon products used in automobiles. The Advanced Polymer Technologies segment produces caprolactone and caprolactone-based specialty polymers. The company generates the majority of its revenue from North America.
62GF Score

Get the complete analysis for FRA:IGX

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€61.50
Price
€36.78
GF Value